Packaging isothermal PCR reagents in blisters and using lateral flow detection, researchers at Boston University hope to develop a low-cost, disposable assay for Bordetella pertussis, the causative agent of whooping cough.
With its acquisition this week of privately held molecular diagnostic developer BioHelix, clinical diagnostics firm Quidel adds to its portfolio of technologies to enable its burgeoning molecular diagnostics business.
BioHelix is developing a low-cost, handheld, real-time fluorescence detection system capable of running assays based on the company's isothermal helicase-dependent amplification technology, the company disclosed this week.
Scientists from Great Basin Scientific and three university medical schools and hospitals have published research demonstrating that Great Basin's molecular diagnostic test for Clostridium difficile is as sensitive and specific as a competing molecular test based on real
This article has been corrected from a previous version that stated that Axxin disclosed in January that it is developing the NAT analyzer and iNAT platforms. In fact, Alere disclosed that it is developing these platforms.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.